145 related articles for article (PubMed ID: 12667537)
1. Cognitive effects of the dopamine receptor agonist pergolide.
Kimberg DY; D'Esposito M
Neuropsychologia; 2003; 41(8):1020-7. PubMed ID: 12667537
[TBL] [Abstract][Full Text] [Related]
2. A functional magnetic resonance imaging study of the effects of pergolide, a dopamine receptor agonist, on component processes of working memory.
Gibbs SE; D'Esposito M
Neuroscience; 2006 Apr; 139(1):359-71. PubMed ID: 16458442
[TBL] [Abstract][Full Text] [Related]
3. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
[TBL] [Abstract][Full Text] [Related]
4. Differential Effects of Pergolide and Bromocriptine on Working Memory Performance and Brain Activation after Mild Traumatic Brain Injury.
Flashman LA; McDonald BC; Ford JC; Kenny RM; Andrews KD; Saykin AJ; McAllister TW
J Neurotrauma; 2021 Jan; 38(2):225-234. PubMed ID: 32635808
[TBL] [Abstract][Full Text] [Related]
5. The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans.
Bartholomeusz CF; Box G; Van Rooy C; Nathan PJ
J Psychopharmacol; 2003 Mar; 17(1):9-15. PubMed ID: 12680735
[TBL] [Abstract][Full Text] [Related]
6. Tonic dopaminergic stimulation impairs associative learning in healthy subjects.
Breitenstein C; Korsukewitz C; Flöel A; Kretzschmar T; Diederich K; Knecht S
Neuropsychopharmacology; 2006 Nov; 31(11):2552-64. PubMed ID: 16880771
[TBL] [Abstract][Full Text] [Related]
7. The effect of pergolide on cognitive performance of young and middle-aged rats.
Küçükatay V; Balkan S; Yaraş N; Yargiçoğlu P; Ağar A
Int J Neurosci; 2002 Sep; 112(9):1027-36. PubMed ID: 12487092
[TBL] [Abstract][Full Text] [Related]
8. D1- versus D2-receptor modulation of visuospatial working memory in humans.
Müller U; von Cramon DY; Pollmann S
J Neurosci; 1998 Apr; 18(7):2720-8. PubMed ID: 9502829
[TBL] [Abstract][Full Text] [Related]
9. Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease.
Mehta MA; Sahakian BJ; McKenna PJ; Robbins TW
Psychopharmacology (Berl); 1999 Sep; 146(2):162-74. PubMed ID: 10525751
[TBL] [Abstract][Full Text] [Related]
10. Combined D1/D2 receptor stimulation under conditions of dopamine depletion impairs spatial working memory performance in humans.
Ellis KA; Mehta MA; Wesnes KA; Armstrong S; Nathan PJ
Psychopharmacology (Berl); 2005 Oct; 181(4):771-80. PubMed ID: 15983794
[TBL] [Abstract][Full Text] [Related]
11. Improved short-term spatial memory but impaired reversal learning following the dopamine D(2) agonist bromocriptine in human volunteers.
Mehta MA; Swainson R; Ogilvie AD; Sahakian J; Robbins TW
Psychopharmacology (Berl); 2001 Dec; 159(1):10-20. PubMed ID: 11797064
[TBL] [Abstract][Full Text] [Related]
12. Effects of hydrocortisone administration on cognitive function in the elderly.
Porter RJ; Barnett NA; Idey A; McGuckin EA; O'Brien JT
J Psychopharmacol; 2002 Mar; 16(1):65-71. PubMed ID: 11949774
[TBL] [Abstract][Full Text] [Related]
13. Sensorimotor effects of pergolide, a dopamine agonist, in healthy subjects: a lateralized readiness potential study.
Rammsayer T; Stahl J
Psychopharmacology (Berl); 2006 Jul; 187(1):36-46. PubMed ID: 16767414
[TBL] [Abstract][Full Text] [Related]
14. [Effect of a dopamine agonist on working memory in monkeys].
Dudkin KN; Chueva IV; Arinbasarov MU; Bobkova NV
Ross Fiziol Zh Im I M Sechenova; 2001 Dec; 87(12):1579-94. PubMed ID: 11840962
[TBL] [Abstract][Full Text] [Related]
15. Individual capacity differences predict working memory performance and prefrontal activity following dopamine receptor stimulation.
Gibbs SE; D'Esposito M
Cogn Affect Behav Neurosci; 2005 Jun; 5(2):212-21. PubMed ID: 16180627
[TBL] [Abstract][Full Text] [Related]
16. Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum.
McClure MM; Harvey PD; Goodman M; Triebwasser J; New A; Koenigsberg HW; Sprung LJ; Flory JD; Siever LJ
Neuropsychopharmacology; 2010 May; 35(6):1356-62. PubMed ID: 20130535
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic modulation of semantic priming in healthy volunteers.
Roesch-Ely D; Weiland S; Scheffel H; Schwaninger M; Hundemer HP; Kolter T; Weisbrod M
Biol Psychiatry; 2006 Sep; 60(6):604-11. PubMed ID: 16603132
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.
Hanna-Pladdy B; Pahwa R; Lyons KE
J Int Neuropsychol Soc; 2015 Apr; 21(4):259-70. PubMed ID: 25923830
[TBL] [Abstract][Full Text] [Related]
19. Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers.
Mehta MA; Manes FF; Magnolfi G; Sahakian BJ; Robbins TW
Psychopharmacology (Berl); 2004 Nov; 176(3-4):331-42. PubMed ID: 15114435
[TBL] [Abstract][Full Text] [Related]
20. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
